Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and Healthcare Products Began Trading on the Nasdaq Global Market Under the Ticker Symbol "ALPS" in October 2025, Marking the Company's Transition to the
Agreement Marks Company’s Expansion into Precision Oncology Testing, with the Goal of Establishing Malaysia's First Clinically Validated PDO Platform KUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology
MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening its Position in Southeast Asian Genomics KUALA LUMPUR, Malaysia, June 09, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (“Alps” or “the Company”) (Nasdaq:
KUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine,
KUALA LUMPUR, Malaysia, April 17, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “ Company ” or “ Alps Group ”), the parent company of Alps Life Sciences Inc. (“ Alps Holdco ”), a biotechnology research and healthcare platform focused on predictive, preventive, and precision medicine, announced the
KUALA LUMPUR, Malaysia, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “Company” or “Alps Group”), the parent company of Alps Life Sciences Inc. (“Alps Holdco”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine,
KUALA LUMPUR, Malaysia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the “ Company ” or “ Alps Group ”), the parent company of Alps Life Sciences Inc. (“ Alps Holdco ”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision
KUALA LUMPUR, Malaysia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (NASDAQ: ALPS) (the “Company” or “Alps Group”), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced the appointment of Cheing
